Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. It focuses on developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications. The firm is developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target, truncated O-glycans on MUC16. The company was founded in 1996 and is headquartered in Edmonton, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company